
News|Articles|March 1, 2002
Expanded role for the P & T Committee: Gaining patient consent for off-label drug use
What's your institution's policy for handling the following situation: A physician wishes to prescribe an FDA-approved drug for an off-label indication for which there is little literature support.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
5


























